{"id":834,"date":"2024-08-18T12:18:00","date_gmt":"2024-08-18T06:48:00","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=834"},"modified":"2024-08-27T18:16:18","modified_gmt":"2024-08-27T12:46:18","slug":"duchenne-muscular-dystrophy-market-insights-epidemiology-and-market-forecast-2020-market-insights-epidemiology-and-market-forecast-2020","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market-insights-epidemiology-and-market-forecast-2020-market-insights-epidemiology-and-market-forecast-2020","title":{"rendered":"Duchenne Muscular Dystrophy: Advances, Challenges, and the Future of Treatment"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a36281deae2d\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a36281deae2d\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market-insights-epidemiology-and-market-forecast-2020-market-insights-epidemiology-and-market-forecast-2020\/#Advancements_in_Duchenne_Muscular_Dystrophy_Treatment\" >Advancements in Duchenne Muscular Dystrophy Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market-insights-epidemiology-and-market-forecast-2020-market-insights-epidemiology-and-market-forecast-2020\/#The_Future_of_Duchenne_Muscular_Dystrophy_Gene_Therapy\" >The Future of Duchenne Muscular Dystrophy Gene Therapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market-insights-epidemiology-and-market-forecast-2020-market-insights-epidemiology-and-market-forecast-2020\/#Beyond_Exon-Skipping_The_Expanding_DMD_Treatment_Landscape\" >Beyond Exon-Skipping: The Expanding DMD Treatment Landscape<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market-insights-epidemiology-and-market-forecast-2020-market-insights-epidemiology-and-market-forecast-2020\/#The_Next_Generation_of_Neuromuscular_Disorder_Therapies\" >The Next Generation of Neuromuscular Disorder Therapies<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market-insights-epidemiology-and-market-forecast-2020-market-insights-epidemiology-and-market-forecast-2020\/#Approved_Therapies_Available_for_Neuromuscular_Disorders_Treatment\" >Approved Therapies Available for Neuromuscular Disorders Treatment<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market-insights-epidemiology-and-market-forecast-2020-market-insights-epidemiology-and-market-forecast-2020\/#The_Path_to_a_Cure_for_Duchenne_Muscular_Dystrophy\" >The Path to a Cure for Duchenne Muscular Dystrophy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market-insights-epidemiology-and-market-forecast-2020-market-insights-epidemiology-and-market-forecast-2020\/#Conclusion\" >Conclusion<\/a><\/li><\/ul><\/nav><\/div>\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"has-text-align-center\">&#8220;<em>Research is the only hope for families affected by Duchenne muscular dystrophy, and every step forward is a step closer to a cure.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p><strong>Duchenne Muscular Dystrophy (DMD)<\/strong> is a severe form of muscular dystrophy characterized by progressive muscle degeneration and weakness. It is a rare disorder, but it is one of the most common genetic conditions, affecting roughly <strong>1 in every 3,500 male births<\/strong> worldwide. Recent advancements in research and treatment have significantly improved the outlook for patients with DMD. In 2023, the total number of prevalent Duchenne Muscular Dystrophy cases across the 7MM (the US, EU5, and Japan) was <strong>approximately 31K<\/strong>. The United States had the highest prevalence, with<strong> around 17K cases<\/strong>. Within the US, the <strong>5-9 year age group<\/strong> had the highest number of cases, followed by the <strong>10-14 year age group<\/strong>. Regardless of whether the numbers rise or fall, this article offers a comprehensive examination of the latest advancements in DMD therapies, encompassing gene therapies, pharmacological treatments, and emerging therapies, along with insights into current market trends and patient-focused strategies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-advancements-in-duchenne-muscular-dystrophy-treatment\"><span class=\"ez-toc-section\" id=\"Advancements_in_Duchenne_Muscular_Dystrophy_Treatment\"><\/span><strong>Advancements in Duchenne Muscular Dystrophy Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Sarepta Therapeutics, a leader in precision genetic medicine for rare diseases, has recently made significant strides in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-market\" class=\"ek-link\">Duchenne muscular dystrophy (DMD) market<\/a> with the FDA&#8217;s approval of <strong>AMONDYS 45 (casimersen).<\/strong> Developed using Sarepta\u2019s phosphorodiamidate morpholino oligomer (PMO) platform, this antisense oligonucleotide is now approved for the treatment of Duchenne muscular dystrophy in patients with a confirmed mutation amenable to <strong>exon 45 skipping<\/strong>. The approval was granted following the demonstration of a statistically significant increase in dystrophin production in skeletal muscle, which is anticipated to offer therapeutic benefits for exon 45-amenable DMD patients. Continued approval of AMONDYS 45 may hinge on the outcomes of ongoing confirmatory trials.<\/p>\n\n\n\n<p>The ESSENCE trial, a placebo-controlled study designed to bolster AMONDYS 45\u2019s approval, is currently ongoing and expected to conclude in 2024. While clinical studies have not shown kidney toxicity, there is a risk of kidney toxicity, including potentially fatal glomerulonephritis, linked to some antisense oligonucleotides. Therefore, regular monitoring of kidney function is recommended for patients receiving AMONDYS 45. The most common adverse reactions, reported in at least 20% of patients, included upper respiratory tract infections, cough, fever, headache, joint pain, and pain in the mouth and throat.<\/p>\n\n\n\n<p>On June 22, 2023, the FDA approved <strong>Sarepta\u2019s <a href=\"https:\/\/www.delveinsight.com\/blog\/elevidys-first-gene-therapy-for-dmd-treatment\">ELEVIDYS<\/a><\/strong>, the <strong>first gene therapy<\/strong> for <a href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-market\">Duchenne muscular dystrophy treatment<\/a>. Sarepta and Roche entered into a collaboration in December 2019, with Roche paying <strong>$1.15 billion<\/strong> upfront for exclusive rights to SRP-9001. It has been the FDA\u2019s 13th gene therapy approval since 2017, and it is the first to address a prevalent genetic disease in <strong>ambulatory pediatric patients aged 4 through 5 years<\/strong>. ELEVIDYS, a one-time treatment, will cost<strong> $3.2 million<\/strong>. In <strong>April 2024, <\/strong>Sarepta forecasted flat sales for its new gene therapy, ELEVIDYS, leading to a first-quarter sales estimate <strong>of $131 million.&nbsp;<\/strong><\/p>\n\n\n\n<p>In June 2024, Sarepta Therapeutics further expanded its impact on the Duchenne muscular dystrophy treatment landscape with the FDA\u2019s approval to broaden the use of <strong>ELEVIDYS (delandistrogene moxeparvovec)<\/strong> for ambulatory DMD patients aged <strong>4 and older.<\/strong> The company also received accelerated approval for non-ambulatory patients. This expansion led to a notable 40% surge in Sarepta\u2019s stock.&nbsp;<\/p>\n\n\n\n<p>This series of approvals and ongoing developments highlights <a href=\"https:\/\/www.delveinsight.com\/blog\/sarepta-therapeutics-dmd-market\" class=\"ek-link\">Sarepta&#8217;s pivotal role in advancing Duchenne muscular dystrophy therapies<\/a>, contributing to the evolving landscape of drugs and treatment options.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-future-of-duchenne-muscular-dystrophy-gene-therapy\"><span class=\"ez-toc-section\" id=\"The_Future_of_Duchenne_Muscular_Dystrophy_Gene_Therapy\"><\/span><strong>The Future of Duchenne Muscular Dystrophy Gene Therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-duchenne-muscular-dystrophy\">Gene therapy for Duchenne Muscular Dystrophy<\/a> is set to transform the Duchenne Muscular Dystrophy treatment landscape by addressing the underlying genetic cause rather than merely managing symptoms. DMD results from mutations in the DMD gene, which encodes the dystrophin protein crucial for muscle cell integrity. The absence or dysfunction of dystrophin leads to progressive muscle degeneration, severe complications, and, ultimately, cardiomyopathy and respiratory failure. Gene therapy aims to introduce a functional version of the dystrophin gene or a microdystrophin gene\u2014an engineered, smaller version retaining essential functions\u2014into patients&#8217; muscle cells. Early trials have shown promise, restoring partial dystrophin production and potentially slowing disease progression.<\/p>\n\n\n\n<p>Gene therapy is emerging as the most promising candidate in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-pipeline-insight\">DMD pipeline<\/a>. Sarepta Therapeutics, a market leader, has successfully launched three of the five DMD drugs currently marketed in the U.S. Sarepta and Pfizer are both in late-stage trials for their<strong> <\/strong>DMD gene therapy candidates. However, Pfizer faces higher stakes, as it lacks additional candidates to fall back on if its therapy fails to gain approval. Recent delays for Pfizer\u2019s candidate, PF-06939926, due to a death in its Phase Ib trial, could give Sarepta\u2019s SRP-9001 a competitive edge. Despite these challenges, Pfizer could still capture a significant share of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-market\">DMD market<\/a> before more gene therapies become available.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-beyond-exon-skipping-the-expanding-dmd-treatment-landscape\"><span class=\"ez-toc-section\" id=\"Beyond_Exon-Skipping_The_Expanding_DMD_Treatment_Landscape\"><\/span><strong>Beyond Exon-Skipping: The Expanding DMD Treatment Landscape<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Exon-skipping therapies are a form of genetic treatment designed to <em>&#8220;skip&#8221; <\/em>over faulty or mutated exons in the DNA sequence, allowing the production of a shorter but functional version of the dystrophin protein in patients with Duchenne muscular dystrophy . By targeting specific exons, these therapies help restore some of the dystrophin production, which is crucial for maintaining muscle strength and function, thereby slowing the progression of the disease. According to a recent analysis by DelveInsight, the Duchenne Muscular Dystrophy market in the 7MM (The United States, Germany, France, Italy, Spain, UK, and Japan) was valued at <strong>USD 2,150 million<\/strong> in <strong>2023 <\/strong>and is projected to experience significant growth during the forecast period from 2024 to 2034. This growth is anticipated due to the launch of <strong>new exon-skipping therapies<\/strong> and the expected approvals of emerging treatments.<\/p>\n\n\n\n<p>Sarepta Therapeutics currently dominates the Duchenne Muscular Dystrophy treatment landscape with a robust pipeline and four approved <strong>antisense oligonucleotide<\/strong> therapies: <strong>EXONDYS 51 (eteplirsen)<\/strong>, approved in September 2016, <strong>VYONDYS 53 (golodirsen), AMONDYS 45 (casimersen), and ELEVIDYS, <\/strong>which received <strong>approval <\/strong>in <strong>June 2023<\/strong>. These therapies target specific mutations in <strong>exon 51, exon 53, exon 45, and exon 8 and\/or exon 9<\/strong>, respectively, collectively addressing approximately 30% of all DMD cases. In June 2024, Sarepta further expanded its market presence by obtaining FDA approval to extend ELEVIDYS to ambulatory DMD patients aged 4 and older, along with accelerated approval for non-ambulatory patients. This approval significantly boosted Sarepta\u2019s market position, leading to a 40% increase in the company&#8217;s stock. For those interested in understanding more about the available treatment options for DMD, these developments in <a href=\"https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market\">exon-skipping therapy<\/a> highlight the ongoing advancements in managing this challenging condition.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-next-generation-of-neuromuscular-disorder-therapies\"><span class=\"ez-toc-section\" id=\"The_Next_Generation_of_Neuromuscular_Disorder_Therapies\"><\/span><strong>The Next Generation of Neuromuscular Disorder Therapies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Neuromuscular disorders (NMD) encompass a wide range of conditions affecting the peripheral nervous system, which links the brain and spinal cord to the body. These include muscular dystrophies, myopathies, motor neuron diseases, ion channel diseases, mitochondrial diseases, neuromuscular diseases, and peripheral nerve diseases. Prominent examples include Duchenne muscular dystrophy, spinal muscular atrophy (SMA), and multiple sclerosis. The prevalence of these disorders is increasingly recognized, highlighting the complex interplay between the nervous system and muscles, and the need for comprehensive management strategies.<\/p>\n\n\n\n<p>According to DelveInsight, the diagnosed <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-market\">prevalence of multiple sclerosis<\/a> in the <strong>7MM<\/strong> was <strong>1.2 million <\/strong>in <strong>2023<\/strong>, with <strong>723K cases<\/strong> in the U.S. The <strong>prevalence of DMD<\/strong> in the <strong>7MM <\/strong>was <strong>31,000<\/strong> in <strong>2023<\/strong>, with the highest proportion of cases in the U.S. observed in the <strong>5-9 year age group<\/strong>. Current research focuses on genetic therapies, novel medications, and nucleic acids such as DNA and RNA, aiming to discover a cure. Meanwhile, management involves symptom control, disease progression slowing, and quality of life improvements through medications, physical therapy, occupational therapy, and surgery.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-approved-therapies-available-for-neuromuscular-disorders-treatment\"><span class=\"ez-toc-section\" id=\"Approved_Therapies_Available_for_Neuromuscular_Disorders_Treatment\"><\/span>Approved Therapies Available for Neuromuscular Disorders Treatment<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>ZOLGENSMA (Onasemnogene abeparvovec-xioi) is the only FDA-approved <a href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases\">gene therapy<\/a> for SMA. SPINRAZA (nusinersen) is an RNA-based antisense oligonucleotide for SMA, developed by Ionis Pharmaceuticals and approved by the FDA in December 2016. EVRYSDI (Risdiplam), the first oral medication for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-muscular-atrophy-market\">treatment of SMA<\/a>, was approved by the FDA in August 2020, showing significant long-term efficacy with 91% of patients alive and 59% able to sit independently for at least 30 seconds after five years of treatment. AMONDYS 45 is an antisense oligonucleotide for DMD, approved by the FDA in February 2021, targeting mutations amenable to exon 45 skipping. ZOLGENSMA was approved by the FDA on May 24, 2019, for the treatment of spinal muscular atrophy (SMA), while SPINRAZA received FDA approval on December 23, 2016.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-path-to-a-cure-for-duchenne-muscular-dystrophy\"><span class=\"ez-toc-section\" id=\"The_Path_to_a_Cure_for_Duchenne_Muscular_Dystrophy\"><\/span><strong>The Path to a Cure for Duchenne Muscular Dystrophy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>For Duchenne muscular dystrophy, treatment has primarily focused on symptom management and improving the quality of life for patients. <a href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-pipeline-insight\">Duchenne Muscular Dystrophy therapies<\/a> currently available in the market include <strong>corticosteroids, steroids, assistive devices, physical therapies,<\/strong> and more. Corticosteroids have been the standard DMD Treatment for strengthening muscles and enhancing lung function. Assistive devices aid patients with breathing difficulties, while orthopedic devices facilitate movement. Steroids, such as prednisone, deflazacort, and oxandrolone, have also proven effective, extending the ability to walk by 2\u20135 years. However, steroid use may lead to side effects, including weight gain, high blood pressure, behavioral changes, and delayed growth.<\/p>\n\n\n\n<p>Some of the notable DMD drugs in the market include <strong>DEFLAZACORT<\/strong>, marketed by <strong>PTC Therapeutics, <\/strong>and <strong>Marathon Pharmaceuticals<\/strong>, which is FDA-approved for treating DMD in patients aged 5 years and older. In June 2024, Cranbury Pharmaceuticals received FDA approval for the generic version of EMFLAZA (deflazacort) for DMD. <strong>Eteplirsen<\/strong>, produced by <strong>Sarepta Therapeutics,<\/strong> is approved for patients with a confirmed mutation of the DMD gene amenable to exon 51 skipping. A March 2024 study titled <em>&#8220;Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy&#8221;<\/em> reported improved survival rates for eteplirsen-treated patients, with a median survival age of 32.8 years, compared to 27.4 years in natural history controls. Additionally, <strong>Ataluren <\/strong>is approved for use in ambulatory patients aged two years and older with nmDMD in the European Union, Iceland, Liechtenstein, Norway, Israel, and South Korea. The current US market features approved products like <strong>EMFLAZA (deflazacort), VYONDYS 53 (golodirsen), EXONDYS 51 (eteplirsen), AMONDYS 45 (casimersen), VILTEPSO (viltolarsen), and ELEVIDYS (delandistrogene moxeparvovec)<\/strong> for treating patients with DMD.<\/p>\n\n\n\n<p>To address various unmet needs in the DMD therapeutical landscape, several randomized trials are being conducted by pharma and biotech companies. These trials are researching new drugs with novel mechanisms of action, such as those with a <strong>high-efficacy\/toxicity ratio to improve outcomes in DMD<\/strong>. Companies like <strong>FibroGen, Santhera Pharmaceutical, Italfarmaco, ReveraGen BioPharma, Cumberland Pharmaceuticals, Sarepta Therapeutics, Antisense Therapeutics, and Capricor Therapeutics among others<\/strong> are working to accelerate advancements in the Duchenne Muscular Dystrophy landscape.<\/p>\n\n\n\n<p>Although there is no cure for muscular dystrophy, treatments for conditions like DMD can extend mobility and improve muscle strength. Key strategies include gene replacement and genetic therapies to restore dystrophin production, stabilize membranes, upregulate compensatory proteins, and reduce inflammation. These advancements represent a<strong> <\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/duchene-muscular-dystrophy-market\" class=\"ek-link\">significant path to cure<\/a>, targeting the underlying genetic causes to enhance patient outcomes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span>Conclusion<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The Duchenne Muscular Dystrophy (DMD) treatment landscape is on the cusp of a transformative era, driven by groundbreaking advancements in gene therapy and precision medicine. With therapies like ELEVIDYS and AMONDYS 45 ushering in a new wave of targeted treatments, there is a tangible shift towards addressing the root genetic causes of DMD. These developments not only enhance the potential for improved patient outcomes but also signal a significant step towards a <em>definitive cure<\/em>. The relentless pursuit of innovation and the promising results from ongoing research highlight a future where DMD may be managed far more effectively, bringing a new level of hope to patients and their families. As the field advances, the integration of cutting-edge therapies promises to revolutionize the standard of care and bring us closer to overcoming this challenging condition.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/23180515\/The-Duchenne-Muscular-Dystrophy-1024x194.jpg\" alt=\"The Duchenne Muscular Dystrophy\" class=\"wp-image-29264\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/23180515\/The-Duchenne-Muscular-Dystrophy-1024x194.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/23180515\/The-Duchenne-Muscular-Dystrophy-300x57.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/23180515\/The-Duchenne-Muscular-Dystrophy-150x28.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/23180515\/The-Duchenne-Muscular-Dystrophy-768x145.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/23180515\/The-Duchenne-Muscular-Dystrophy-1536x291.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/23180515\/The-Duchenne-Muscular-Dystrophy.jpg 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Research is the only hope for families affected by Duchenne muscular dystrophy, and every step forward is a step closer to a cure.&#8221; Duchenne Muscular Dystrophy (DMD) is a severe form of muscular dystrophy characterized by progressive muscle degeneration and weakness. It is a rare disorder, but it is one of the most common genetic [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":29320,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[134,173,180,204,356,374,383,384,386,484,529,550],"industry":[17225],"therapeutic_areas":[17238,17241,17234],"class_list":["post-834","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-business-consultant","tag-collaborations","tag-competitive-landscape","tag-delveinsight","tag-licensing-opportunities","tag-market-forecasting","tag-market-segments","tag-market-size-7mm","tag-market-trends","tag-pipeline-products-and-technologies","tag-sales-forecasting","tag-swot-analysis","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-musculoskeletal","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>DMD: Latest Treatments, Gene Therapy, and Market Trends<\/title>\n<meta name=\"description\" content=\"Advancements in Duchenne Muscular Dystrophy treatment, including exon-skipping therapies, gene therapy, market trends, and future prospects.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market-insights-epidemiology-and-market-forecast-2020-market-insights-epidemiology-and-market-forecast-2020\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DMD: Latest Treatments, Gene Therapy, and Market Trends\" \/>\n<meta property=\"og:description\" content=\"Advancements in Duchenne Muscular Dystrophy treatment, including exon-skipping therapies, gene therapy, market trends, and future prospects.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market-insights-epidemiology-and-market-forecast-2020-market-insights-epidemiology-and-market-forecast-2020\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-18T06:48:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-27T12:46:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/26110618\/Duchenne-Muscular-Dystrophy-Advances-Challenges-and-the-Future-of-Treatment.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"DMD: Latest Treatments, Gene Therapy, and Market Trends","description":"Advancements in Duchenne Muscular Dystrophy treatment, including exon-skipping therapies, gene therapy, market trends, and future prospects.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market-insights-epidemiology-and-market-forecast-2020-market-insights-epidemiology-and-market-forecast-2020","og_locale":"en_US","og_type":"article","og_title":"DMD: Latest Treatments, Gene Therapy, and Market Trends","og_description":"Advancements in Duchenne Muscular Dystrophy treatment, including exon-skipping therapies, gene therapy, market trends, and future prospects.","og_url":"https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market-insights-epidemiology-and-market-forecast-2020-market-insights-epidemiology-and-market-forecast-2020","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-08-18T06:48:00+00:00","article_modified_time":"2024-08-27T12:46:18+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/26110618\/Duchenne-Muscular-Dystrophy-Advances-Challenges-and-the-Future-of-Treatment.jpg","type":"image\/jpeg"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market-insights-epidemiology-and-market-forecast-2020-market-insights-epidemiology-and-market-forecast-2020","url":"https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market-insights-epidemiology-and-market-forecast-2020-market-insights-epidemiology-and-market-forecast-2020","name":"DMD: Latest Treatments, Gene Therapy, and Market Trends","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market-insights-epidemiology-and-market-forecast-2020-market-insights-epidemiology-and-market-forecast-2020#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market-insights-epidemiology-and-market-forecast-2020-market-insights-epidemiology-and-market-forecast-2020#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/26110618\/Duchenne-Muscular-Dystrophy-Advances-Challenges-and-the-Future-of-Treatment.jpg","datePublished":"2024-08-18T06:48:00+00:00","dateModified":"2024-08-27T12:46:18+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Advancements in Duchenne Muscular Dystrophy treatment, including exon-skipping therapies, gene therapy, market trends, and future prospects.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market-insights-epidemiology-and-market-forecast-2020-market-insights-epidemiology-and-market-forecast-2020"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market-insights-epidemiology-and-market-forecast-2020-market-insights-epidemiology-and-market-forecast-2020#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/26110618\/Duchenne-Muscular-Dystrophy-Advances-Challenges-and-the-Future-of-Treatment.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/26110618\/Duchenne-Muscular-Dystrophy-Advances-Challenges-and-the-Future-of-Treatment.jpg","width":466,"height":284,"caption":"Duchenne Muscular Dystrophy Advances Challenges and the Future of Treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/26110618\/Duchenne-Muscular-Dystrophy-Advances-Challenges-and-the-Future-of-Treatment-300x183.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Business Consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">collaborations<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Competitive landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">licensing opportunities<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Market Forecasting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Market segments<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Market size (7MM)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">market trends<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pipeline products and technologies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Sales forecasting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">SWOT ANALYSIS<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Business Consultant<\/span>","<span class=\"advgb-post-tax-term\">collaborations<\/span>","<span class=\"advgb-post-tax-term\">Competitive landscape<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">licensing opportunities<\/span>","<span class=\"advgb-post-tax-term\">Market Forecasting<\/span>","<span class=\"advgb-post-tax-term\">Market segments<\/span>","<span class=\"advgb-post-tax-term\">Market size (7MM)<\/span>","<span class=\"advgb-post-tax-term\">market trends<\/span>","<span class=\"advgb-post-tax-term\">Pipeline products and technologies<\/span>","<span class=\"advgb-post-tax-term\">Sales forecasting<\/span>","<span class=\"advgb-post-tax-term\">SWOT ANALYSIS<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Aug 18, 2024","modified":"Updated on Aug 27, 2024"},"absolute_dates_time":{"created":"Posted on Aug 18, 2024 12:18 pm","modified":"Updated on Aug 27, 2024 6:16 pm"},"featured_img_caption":"Duchenne Muscular Dystrophy Advances Challenges and the Future of Treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=834"}],"version-history":[{"count":5,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/834\/revisions"}],"predecessor-version":[{"id":29355,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/834\/revisions\/29355"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/29320"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=834"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=834"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=834"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=834"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}